Zoetis: quality near the top of our coverage, sitting in the sweet spot near its 52-week low

## Why Zoetis stands out today

Zoetis (ZTS), the animal-health company spun out of Pfizer, screens today as one of the more interesting combinations of quality and projected return in our coverage. At a quality percentile of 95.1 (ranking ahead of roughly 95% of the companies we follow), Zoetis carries a Projected Annual Return (PAR) of 18.5%. PAR is our forward-looking estimate of annualized total return over roughly the next five years, built from a sales growth forecast, projected margins, and the P/E the market is likely to assign at the end of that stretch. With MIPAR (the median PAR across everything we follow) at 8.8%, the sweet spot we look for runs from 13.8% to 18.8% (MIPAR + 5 to +10 points). Zoetis's 18.5% PAR puts it right near the top of that band, comfortably inside it.

A few supporting data points:

- **Financial strength**: 91 out of 100, a solid balance sheet reading.
- **EPS stability**: 97.7 out of 100, among the smoothest earnings track records we track.
- **Core Score**: 284 out of 300 (quality percentile + financial strength + EPS stability, each on their own 0-100 scale). Anything above 225 is the threshold we associate with "core holding" candidates, so 284 is well past it.
- **Price positioning**: shares sit at $75.10, just 5.1% above the 52-week low of $71.47 and 53.6% below the 52-week high of $161.77. That's a meaningful pullback from the annual high, and it's part of why the projected return looks as attractive as it does. PAR moves inversely to price: when the price falls and the fundamentals hold, the projected return rises.
- **Growth and yield**: the growth forecast embedded in the model is 5.3%, current dividend yield is 2.65%, with a projected yield of 1.7%. The current P/E is 17.5.

**Why today specifically**: Zoetis reports next-quarter earnings on August 6, 2026, giving investors a concrete near-term checkpoint. On the operating side, Zoetis also picked up European Commission approval this week for a new poultry vaccine, one small data point on the pipeline side of the business.

For context, the Wall Street consensus price target across covering analysts is $110.57, per our data aggregator. We mention that as an outside reference point only, not as a blend with our own PAR methodology, which are two different lenses on the stock.

As always, this is a research lens, not a recommendation. The combination of high quality, a sweet-spot PAR, and proximity to a 52-week low is the kind of setup worth studying more closely, not a signal to act on by itself.